AKANDA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.103 USD | +12.57% |
|
+9.11% | -76.62% |
Financials (USD)
| Sales 2021 | 0.04 | Sales 2022 | 2.62 | Capitalization | 4.83M |
|---|---|---|---|---|---|
| Net income 2021 | -8M | Net income 2022 | -11M | EV / Sales 2021 * | - |
| Net Debt 2021 | 6.07 | Net Debt 2022 | 3.41 | EV / Sales 2022 | 1,845,597 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-0.38
x | Employees | 46 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 85.98% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +12.57% | ||
| 1 week | +9.11% | ||
| Current month | -11.66% | ||
| 1 month | -11.66% | ||
| 3 months | -74.87% | ||
| 6 months | -77.95% | ||
| Current year | -76.62% |
1 week
0.09
0.11
1 month
0.090.19
Current year
0.090.71
1 year
0.092.70
3 years
0.09310.00
5 years
0.09310.00
10 years
0.09310.00
| Managers | Title | Age | Since |
|---|---|---|---|
Katharyn Field
CEO | Chief Executive Officer | 41 | 22-06-22 |
Bruno Gancho
DFI | Director of Finance/CFO | - | - |
| President | 45 | 21-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jay Dhaliwal
BRD | Director/Board Member | 36 | 22-06-22 |
Katharyn Field
CEO | Chief Executive Officer | 41 | 22-06-22 |
David Jenkins
BRD | Director/Board Member | - | 23-02-12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.103 | +12.57% | 3,729,289 |
| 24-04-25 | 0.0915 | +2.01% | 1,601,343 |
| 24-04-24 | 0.0897 | -2.39% | 1,808,167 |
| 24-04-23 | 0.0919 | +0.66% | 2,849,616 |
| 24-04-22 | 0.0913 | -3.28% | 7,308,759 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Akanda Corp. is an international medical cannabis and wellness platform company. The Companyâs portfolio includes Canmart Ltd. (CanMart), a United Kingdom-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the United Kingdom. Canmart is a licensed importer and distributor of CBD Extraction for Medicinal Purposes (CBPMs) in the United Kingdom. CanMart holds a controlled drug license issued by the Home Office to possess and supply CBPMs in the United Kingdom. The Company's seed-to-patient supply chain also includes partnerships Cellen Life Sciences' Leva Clinic, a fully digital pain clinic in the United Kingdom. The Company also develops a Canadian farming property in British Columbia, including farming land and related operations and licenses. The Company also focuses on developing tetrahydrocannabinol (THC) and cannabinoid (CBD) facilities at this site.
| 1st Jan change | Capi. | |
|---|---|---|
| -76.62% | 872K | |
| +31.96% | 272M | |
| +33.74% | 261M | |
| +49.42% | 194M | |
| +44.98% | 131M | |
| -28.57% | 121M | |
| +115.91% | 119M | |
| -42.17% | 119M | |
| 0.00% | 86.82M | |
| +150.00% | 75.33M |
- Stock Market
- Equities
- AKAN Stock
